- First tibolone-based hormone treatment available in Canada, offering a new treatment option for menopausal women
- Mithra’s product commercialized by BioSyent Pharma for a growing annual market value of
EUR 132 million
- Canadian launch generates additional revenues for Mithra through sales related milestones
Liege, Belgium, 30 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the commercial launch of tibolone-based product Tibelia® in Canada. Developed by Mithra as the bioequivalent version of Livial®1, Tibelia® is a synthetic steroid that relieves postmenopausal symptoms and prevents osteoporosis in postmenopausal women at
high risk of future fractures who are intolerant of other medicinal products. Mithra’s product is marketed by BioSyent Pharma Inc. (TSX Venture Exchange: RX) in Canada under the trademark name Tibella®.